Skip to the page

Data / Public companies / SIC 8731: Commercial physical and biological research / Cannabis Bioscience International Holdings, Inc.

Cannabis Bioscience International Holdings, Inc.: revenue, net income and total assets from its latest annual report

Updated September 22, 2025. Source: SEC Financial Statement Data Sets, filing 0001683168-25-007174.

Cannabis Bioscience International Holdings, Inc. reported revenue of $303,022, a net loss of $548,820 and total assets of $31,880 for the fiscal year ended May 31, 2025, in its annual report (10-K) filed with the SEC on September 22, 2025. It ranks 15th by revenue of 15 companies in SIC 8731, commercial physical and biological research.

The request: Watch Cannabis Bioscience International Holdings, Inc. (CIK 1411057): each new SEC filing, with revenue and net income. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the annual reports that companies file with the SEC, and this page is that reading. Ask for the companies of an industry, state or city with their website, number of employees and funding added from the web, and each new annual report arrives in your sheet, CRM, Slack or agent as the SEC posts it.

SEC central index key (CIK)
1411057
Industry
SIC 8731, Commercial physical and biological research
Business address (city and state)
Houston, Texas
Filer category
Non-accelerated filer
Fiscal year ends
May 31
Latest annual report
10-K filed September 22, 2025
Annual and quarterly reports in the data
1 annual, 3 quarterly

Financials for the fiscal year ended May 31, 2025

As filed, in US dollars. The prior year value is the comparison column in the same report.

ItemThis yearPrior yearChangeSource
Revenue$303,022$248,84121.8%sec.gov
Operating income$-421,365Not listedNot listedsec.gov
Net income$-548,820$-651,34515.7%sec.gov
Total assets$31,880$57,162-44.2%sec.gov
Total liabilities$1,195,463Not listedNot listedsec.gov
Stockholders' equity$-1,163,583Not listedNot listedsec.gov
Cash and cash equivalents$12,952Not listedNot listedsec.gov

How it compares

Net margin (net income over revenue)
-181.1%
Revenue change on the prior year
21.8%
Revenue rank in SIC 8731
15th of 15
Revenue rank in Texas
395th of 408
Revenue rank among all companies in the data
4,259th of 4,486

Companies next to it by revenue in SIC 8731

Commercial physical and biological research, from the same data.

CompanyBusiness addressRevenueNet incomeTotal assetsRevenue change
National Research CorpLincoln, NE$137.4 million$11.6 million$134.9 million-4%
Maxcyte, Inc.Rockville, MD$33 million$-44,630,000$202.5 million-14.5%
Omniab, Inc.Emeryville, CA$18.7 million$-64,779,000$300.9 million-29.3%
Foxo Technologies Inc.West Palm Beach, FL$16.4 million$-12,430,390$44.6 million304%
Bioaffinity Technologies, Inc.San Antonio, TX$6.2 million$-14,909,754$11 million-34.2%
Absci CorpVancouver, WA$2.8 million$-115,183,000$216.3 million-38.2%
Ispecimen Inc.Woburn, MA$1.9 million$-10,487,532$9.5 million-79.2%
Onemednet CorpSurrey, United Kingdom$1.4 million$-2,801,000$2.2 million111.4%

Public data from the US Securities and Exchange Commission. Companies are the registrants whose latest annual report (form 10-K, 20-F or 40-F) is in the SEC Financial Statement Data Sets for 2025 Q3 to 2026 Q3, filed through September 30, 2026. Figures are for the whole fiscal year of that report, in US dollars, as the company filed them in XBRL: SpecStream does not adjust them. The SEC does not guarantee the data sets, and they do not replace the filings. Revenue is the revenue tag the company used; banks and funds often use none. Combined totals add each company once and can include a parent and its subsidiary that both file. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.